TARO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TARO, and what generic alternatives to TARO drugs are available?
TARO has two hundred and fifty-seven approved drugs.
There are five US patents protecting TARO drugs. There are four tentative approvals on TARO drugs.
There are twenty-four patent family members on TARO drugs in eleven countries and one hundred and ninety supplementary protection certificates in fifteen countries.
Summary for TARO
| International Patents: | 24 |
| US Patents: | 5 |
| Tradenames: | 135 |
| Ingredients: | 118 |
| NDAs: | 257 |
| Patent Litigation for TARO: | See patent lawsuits for TARO |
| PTAB Cases with TARO as petitioner: | See PTAB cases with TARO as petitioner |
Drugs and US Patents for TARO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taro | WARFARIN SODIUM | warfarin sodium | TABLET;ORAL | 040301-009 | Jul 15, 1999 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Taro | ACETAMINOPHEN | acetaminophen | SUPPOSITORY;RECTAL | 018337-002 | Approved Prior to Jan 1, 1982 | OTC | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Taro | AMMONIUM LACTATE | ammonium lactate | LOTION;TOPICAL | 076216-001 | May 28, 2004 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Taro | FLUPHENAZINE HYDROCHLORIDE | fluphenazine hydrochloride | TABLET;ORAL | 215674-003 | Apr 14, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Taro | CICLOPIROX | ciclopirox | SHAMPOO;TOPICAL | 090269-001 | Feb 23, 2011 | AT | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Taro | ONDANSETRON HYDROCHLORIDE | ondansetron hydrochloride | TABLET;ORAL | 077729-002 | Mar 28, 2011 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TARO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-002 | Jan 17, 2008 | 6,656,482 | ⤷ Subscribe |
| Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-002 | Jan 17, 2008 | 6,071,523 | ⤷ Subscribe |
| Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-001 | Jan 17, 2008 | 6,102,254 | ⤷ Subscribe |
| Taro | TOPICORT | desoximetasone | SPRAY;TOPICAL | 204141-001 | Apr 11, 2013 | 5,990,100 | ⤷ Subscribe |
| Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-002 | Jan 17, 2008 | 6,102,254 | ⤷ Subscribe |
| Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-001 | Jan 17, 2008 | 6,656,482 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TARO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Spray | 0.25% | ➤ Subscribe | 2013-12-18 |
| ➤ Subscribe | Topical Lotion | 0.5% | ➤ Subscribe | 2011-03-16 |
International Patents for TARO Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2616112 | ⤷ Subscribe |
| Japan | 2013014634 | ⤷ Subscribe |
| Australia | 2006278620 | ⤷ Subscribe |
| South Africa | 200800926 | ⤷ Subscribe |
| China | 103087095 | ⤷ Subscribe |
| Brazil | PI0612686 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TARO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1666481 | 17C1031 | France | ⤷ Subscribe | PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
| 2435024 | 21C1020 | France | ⤷ Subscribe | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210 |
| 0266730 | SPC/GB97/005 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926 |
| 2822954 | 1890030-8 | Sweden | ⤷ Subscribe | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
| 0984957 | CR 2012 00035 | Denmark | ⤷ Subscribe | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105 |
| 1519731 | 13C0067 | France | ⤷ Subscribe | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
